Overview
Compare with Microvast Holdings, Inc., Fluence Energy, Inc. or HRG Group, or pick any stock.
- TickerNOVT on Nasdaq1
- IndustryMiscellaneous Electrical Machinery, Equipment & Supplies1
- HeadquartersBedford, Massachusetts1
- Incorporated inNew Brunswick, Canada2
- Business address125 Middlesex Turnpike, ., Bedford, Ma 017302
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
Novanta Inc. and its subsidiaries (collectively referred to as the “Company”, “Novanta”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables us to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
44.4%Gross margin5
9.6%Operating margin5
5.5%Net margin5
3.3%Revenue growth, 20255
4.1%Return on equity5
0.16×Debt to equity5
$48.4MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Automation Enabling Technologies brought in 51% of the revenue NOVANTA INC broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Automation Enabling Technologies | $499.2M | $490.6M | $500.8M |
| Medical Solutions | $382.4M | $458.6M | $479.8M |
Regions
United States brought in 53% of the revenue NOVANTA INC broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $418.3M | $487.1M | $519.0M |
| Rest Of Europe | $137.0M | $128.9M | $137.4M |
| Germany | $128.2M | $123.2M | $114.6M |
| Rest Of Asia Pacific | $105.3M | $107.1M | $97.0M |
| China | $73.4M | $84.6M | $93.2M |
| Other Countries | $19.3M | $18.4M | $19.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue56¢$545.3M
- Research and development10¢$95.5M
- Selling, general and admin20¢$195.7M
- Other costs8¢$74.5M
- Income tax2¢$15.8M
- Profit5¢$53.8M
Out of $980.6M in revenue.5
Where each dollar of operating cash went, fiscal 2025
- Capital spending24¢$15.6M
- Share buybacks61¢$39.3M
- Kept or used elsewhere14¢$9.2M
Out of $64.1M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $980.6M | $949.2M | $881.7M |
| Cost of revenue | $545.3M | $527.7M | $481.8M |
| Gross profit | $435.3M | $421.5M | $399.9M |
| Research and development and engineering | $95.5M | $95.5M | $91.7M |
| Selling, general and administrative | $195.7M | $175.9M | $164.5M |
| Amortization of purchased intangible assets | $27.5M | $25.8M | $20.4M |
| Restructuring, acquisition and related costs | $22.7M | $13.7M | $12.8M |
| Total operating expenses | $341.3M | $311.0M | $289.4M |
| Operating income | $94.0M | $110.6M | $110.5M |
| Interest income (expense), net | -$21.5M | -$31.5M | -$25.8M |
| Foreign exchange transaction gains (losses), net | -$2.2M | $413.0K | -$255.0K |
| Other income (expense), net | -$708.0K | -$442.0K | -$675.0K |
| Income before income taxes | $69.6M | $79.1M | $83.7M |
| Income tax provision | $15.8M | $15.0M | $10.9M |
| Net income | $53.8M | $64.1M | $72.9M |
| Basic | $1.47 | $1.78 | $2.03 |
| Diluted | $1.47 | $1.77 | $2.02 |
| Weighted average common shares outstandingbasic | 36.6M shares | 36.0M shares | 35.8M shares |
| Weighted average common shares outstandingdiluted | 36.7M shares | 36.1M shares | 36.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $380.9M | $114.0M | |||
| Accounts receivable, net of allowance of $1,341 and $505, respectively | $184.9M | $151.0M | |||
| Inventories | $188.3M | $144.6M | |||
| Prepaid income taxes and income taxes receivable | $9.4M | $8.1M | |||
| Prepaid expenses and other current assets | $19.2M | $16.0M | |||
| Total current assets | $782.6M | $433.6M | |||
| Property, plant and equipment, net | $118.5M | $113.1M | |||
| Operating right-of-use assets | $41.7M | $42.9M | |||
| Deferred tax assets | $27.4M | $22.9M | |||
| Other assets | $8.8M | $6.0M | |||
| Intangible assets, net | $180.8M | $185.8M | |||
| Goodwill | $647.3M | $584.1M | |||
| Total assets | $1.8B | $1.4B | |||
| Current portion of long-term debt | $38.3M | $4.7M | |||
| Accounts payable | $94.9M | $76.9M | |||
| Income taxes payable | $5.9M | $16.0M | |||
| Current portion of operating lease liabilities | $9.9M | $9.9M | |||
| Accrued expenses and other current liabilities | $63.5M | $60.3M | |||
| Total current liabilities | $212.4M | $167.8M | |||
| Long-term debt | $212.5M | $411.9M | |||
| Operating lease liabilities | $38.9M | $40.5M | |||
| Deferred tax liabilities | $18.1M | $13.1M | |||
| Income taxes payable | $4.0M | $4.9M | |||
| Other liabilities | $7.0M | $4.5M | |||
| Total liabilities | $492.8M | $642.8M | |||
| Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 35,671 and 35,938, respectively | $423.9M | $423.9M | |||
| Additional paid-in capital | $572.1M | $84.2M | |||
| Retained earnings | $321.4M | $267.5M | |||
| Accumulated other comprehensive loss | -$3.0M | -$29.9M | |||
| Total stockholders' equity | $1.3B | $745.7M | |||
| Total liabilities and stockholders equity | $1.8B | $1.4B | |||
| Accounts receivable, allowance | $1.3M | $505.0K | $571.0K | $995.0K | |
| Preferred shares, no par value | $0 | $0 | |||
| Preferred shares, Authorized | 7.0M shares | 7.0M shares | 7.0M shares | ||
| Preferred shares, Issued | 0 shares | 0 shares | |||
| Preferred shares, outstanding | 0 shares | 0 shares | |||
| Common shares, no par value | $0 | $0 | |||
| Common shares, Issued | 35.7M shares | 35.9M shares | |||
| Common shares, outstanding | 35.7M shares | 35.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $380.9M | $114.0M | |||
| Accounts receivable, net of allowance of $1,341 and $505, respectively | $184.9M | $151.0M | |||
| Inventories | $188.3M | $144.6M | |||
| Prepaid income taxes and income taxes receivable | $9.4M | $8.1M | |||
| Prepaid expenses and other current assets | $19.2M | $16.0M | |||
| Total current assets | $782.6M | $433.6M | |||
| Property, plant and equipment, net | $118.5M | $113.1M | |||
| Operating right-of-use assets | $41.7M | $42.9M | |||
| Deferred tax assets | $27.4M | $22.9M | |||
| Other assets | $8.8M | $6.0M | |||
| Intangible assets, net | $180.8M | $185.8M | |||
| Goodwill | $647.3M | $584.1M | |||
| Total assets | $1.8B | $1.4B | |||
| Current portion of long-term debt | $38.3M | $4.7M | |||
| Accounts payable | $94.9M | $76.9M | |||
| Income taxes payable | $5.9M | $16.0M | |||
| Current portion of operating lease liabilities | $9.9M | $9.9M | |||
| Accrued expenses and other current liabilities | $63.5M | $60.3M | |||
| Total current liabilities | $212.4M | $167.8M | |||
| Long-term debt | $212.5M | $411.9M | |||
| Operating lease liabilities | $38.9M | $40.5M | |||
| Deferred tax liabilities | $18.1M | $13.1M | |||
| Income taxes payable | $4.0M | $4.9M | |||
| Other liabilities | $7.0M | $4.5M | |||
| Total liabilities | $492.8M | $642.8M | |||
| Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 35,671 and 35,938, respectively | $423.9M | $423.9M | |||
| Additional paid-in capital | $572.1M | $84.2M | |||
| Retained earnings | $321.4M | $267.5M | |||
| Accumulated other comprehensive loss | -$3.0M | -$29.9M | |||
| Total stockholders' equity | $1.3B | $745.7M | |||
| Total liabilities and stockholders equity | $1.8B | $1.4B | |||
| Accounts receivable, allowance | $1.3M | $505.0K | $571.0K | $995.0K | |
| Preferred shares, no par value | $0 | $0 | |||
| Preferred shares, Authorized | 7.0M shares | 7.0M shares | 7.0M shares | ||
| Preferred shares, Issued | 0 shares | 0 shares | |||
| Preferred shares, outstanding | 0 shares | 0 shares | |||
| Common shares, no par value | $0 | $0 | |||
| Common shares, Issued | 35.7M shares | 35.9M shares | |||
| Common shares, outstanding | 35.7M shares | 35.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $53.8M | $64.1M | $72.9M |
| Depreciation and amortization | $61.9M | $55.6M | $46.6M |
| Provision for inventory excess and obsolescence | $3.3M | $8.8M | $7.5M |
| Impairment of operating lease assets | $1.9M | ||
| Share-based compensation | $29.5M | $23.3M | $25.6M |
| Deferred income taxes | -$8.9M | -$15.9M | -$14.7M |
| Loss (gain) on disposal of fixed assets | -$4.1M | -$64.0K | $148.0K |
| Contingent consideration adjustments | $830.0K | -$282.0K | |
| Inventory acquisition fair value adjustments | $2.8M | ||
| Write-off of unamortized deferred financing costs | $426.0K | ||
| Non-cash interest expense | $1.5M | $1.2M | $1.2M |
| Other non-cash items | $857.0K | $170.0K | $397.0K |
| Accounts receivable, net of allowance | -$27.3M | -$6.2M | -$127.0K |
| Inventories | -$36.1M | $4.8M | $11.4M |
| Prepaid expenses and other current assets | -$1.3M | -$1.5M | $709.0K |
| Prepaid income taxes, income taxes receivable and income taxes payable | -$12.4M | $9.0M | -$12.3M |
| Accounts payable, accrued expenses and other current liabilities | $3.7M | $13.1M | -$20.5M |
| Other non-current assets and liabilities | -$1.8M | -$253.0K | -$474.0K |
| Cash provided by operating activities | $64.1M | $158.5M | $120.1M |
| Purchases of property, plant and equipment | -$15.6M | -$17.2M | -$20.0M |
| Acquisition of businesses, net of cash acquired and working capital adjustments | -$64.3M | -$191.2M | |
| Proceeds from sale of property, plant and equipment | $5.6M | $173.0K | $69.0K |
| Cash used in investing activities | -$74.3M | -$208.2M | -$19.9M |
| Borrowings under revolving credit facilities | $82.8M | $198.0M | |
| Proceeds from issuance of tangible equity units, net of issuance costs | $614.4M | ||
| Repayments under term loan and revolving credit facilities | -$365.7M | -$131.1M | -$86.6M |
| Payments of debt issuance costs | -$4.7M | $0 | |
| Payments of withholding taxes from share-based awards | -$7.8M | -$9.7M | -$10.6M |
| Payments of contingent considerations related to acquisitions | $0 | $0 | -$81.0K |
| Repurchases of common shares | -$39.3M | ||
| Other financing activities | -$3.3M | -$278.0K | -$657.0K |
| Cash provided by (used in) financing activities | $276.3M | $56.9M | -$97.9M |
| Effect of exchange rates on cash and cash equivalents | $818.0K | $1.7M | $2.6M |
| Increase (decrease) in cash and cash equivalents | $266.9M | $8.9M | $4.9M |
| Cash paid for interest | $22.6M | $32.7M | $25.3M |
| Cash paid for income taxes | $38.7M | $21.2M | $36.9M |
| Income tax refunds received | $1.9M | $1.6M | $612.0K |
| Accruals for capital expenditures | $1.1M | $2.5M | $570.0K |
No quarter-by-quarter statement was filed.
Corporate structure
NOVANTA INC sits at the top of its group. 31 entities, 13 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of NOVANTA INC
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G on NOVANTA INC, latest Aug 14, 2026 (6 filings since Feb 14, 2022)
- BlackRock Filed SCHEDULE 13G/A on NOVANTA INC, latest Jul 30, 2026 (5 filings since Feb 3, 2022)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on NOVANTA INC, latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on NOVANTA INC, latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on NOVANTA INC, latest Mar 27, 2026 (6 filings since Feb 10, 2022)
- Neuberger Berman Filed SC 13G/A on NOVANTA INC, latest Feb 10, 2023 (2 filings since Feb 14, 2022)
- NOVANTA INC Bedford, Massachusetts
- ATI Automatizacion Industrial S de RL de CV. Subsidiary · Mexico
- ATI Industrial Automation (Lang Fang) Co., Ltd. Subsidiary · China
- ATI Industrial Automation, Inc. Subsidiary · North Carolina, United States
- ATI Industrial Mexico, LLC Subsidiary · North Carolina, United States
- Bearing Engineers, Inc. d/b/a Motion Solutions Subsidiary · California, United States
- GSI Lumonics Asia Pacific Ltd. Subsidiary · Hong Kong
- iBex Motion, LLC Subsidiary · California, United States
- Keonn Technologies, S.L. Subsidiary · Spain
- Laser Quantum Limited Subsidiary · United Kingdom
- Motion Solutions Parent Corp Subsidiary · Delaware, United States
- NDS Surgical Imaging, LLC Subsidiary · Delaware, United States
- Novanta Distribution (USD) GmbH Subsidiary · Germany
- Novanta Europe GmbH Subsidiary · Germany
- Novanta Holdings BV Subsidiary · Netherlands
- Novanta Insurance Company Subsidiary · Arizona, United States
- Novanta Italy SRL Subsidiary · Italy
- Novanta Japan Corporation Subsidiary · Japan
- Novanta Medical GmbH Subsidiary · Germany
- Novanta Medical s.r.o. Subsidiary · Czechia
- Novanta Medical Technologies Corp. Subsidiary · Delaware, United States
- Novanta Medical USA, Inc.. Subsidiary · Florida, United States
- Novanta Precision Medicine Corporation Subsidiary · Delaware, United States
- Novanta Singapore Pte. Ltd. Subsidiary · Singapore
- Novanta Technologies (Suzhou) Co., Ltd. Subsidiary · China
- Novanta Technologies Spain, S.L.. Subsidiary · Spain
- and 5 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What NOVANTA INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $251.1M5 Dec 31, 2025 | $224.9M5 Dec 31, 2024 | +11.6% |
| Accumulated depreciation | $132.6M5 Dec 31, 2025 | $111.8M5 Dec 31, 2024 | +18.6% |
| Property and equipment, net | $118.5M5 Dec 31, 2025 | $113.1M5 Dec 31, 2024 | +4.7% |
| Finance-lease assets | $2.1M5 Dec 31, 2025 | $2.7M5 Dec 31, 2024 | −22.2% |
| Operating-lease assets (leased space) | $41.7M5 Dec 31, 2025 | $42.9M5 Dec 31, 2024 | −2.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $380.9M5 Dec 31, 2025 | $114.0M5 Dec 31, 2024 | +234.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $647.3M5 Dec 31, 2025 | $584.1M5 Dec 31, 2024 | +10.8% |
| Intangible assets, net (excluding goodwill) | $180.8M5 Dec 31, 2025 | $185.8M5 Dec 31, 2024 | −2.7% |
| Trademarks and trade names (indefinite-lived) | $13.0M5 Dec 31, 2025 | $13.0M5 Dec 31, 2024 | 0% |
| Finite-lived intangibles, gross | $558.0M5 Dec 31, 2025 | $507.4M5 Dec 31, 2024 | +10.0% |
| Accumulated amortization | $390.2M5 Dec 31, 2025 | $334.6M5 Dec 31, 2024 | +16.6% |
| Finite-lived intangibles, net | $167.7M5 Dec 31, 2025 | $172.8M5 Dec 31, 2024 | −2.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $188.3M5 Dec 31, 2025 | $144.6M5 Dec 31, 2024 | +30.2% |
| Raw materials | $123.3M5 Dec 31, 2025 | $92.2M5 Dec 31, 2024 | +33.7% |
| Work in process | $32.5M5 Dec 31, 2025 | $24.7M5 Dec 31, 2024 | +31.4% |
| Finished goods | $31.7M5 Dec 31, 2025 | $27.3M5 Dec 31, 2024 | +16.1% |
Properties, in its own words
Our principal owned and leased properties as of December 31, 2025 are listed in the table below.
Location · Principal Use · Current Segment · Approximate Square Feet · Owned/Leased
The rest of Item 2
Bedford, MassachusettsUnited States · Manufacturing, R&D, Marketing, Sales and Administration · Automation Enabling Technologies, Medical Solutions, Corporate · 147,000 · Leased; expires in 2031
Apex, North CarolinaUnited States · Manufacturing, R&D, Marketing, Sales and Administration · Automation Enabling Technologies · 117,000 · Leased; expires in 2028
LudwigsstadtGermany · Manufacturing and Administration · Medical Solutions · 105,000 · Owned
PřeloučCzech Republic · Manufacturing and Administration · Medical Solutions · 95,000 · Owned
SuzhouChina · Manufacturing, Marketing and Sales · Automation Enabling Technologies and Medical Solutions · 55,000 · Leased; expires in 2028
StockportUnited Kingdom · Manufacturing, R&D, Sales and Administration · Automation Enabling Technologies and Medical Solutions · 44,000 · Leased; expires in 2036
TauntonUnited Kingdom · Manufacturing, Sales and Administration · Automation Enabling Technologies · 33,000 · Leased; expires in 2034
Additional manufacturing, research and development, sales, service and logistics sites are located in California, Connecticut, Florida, Michigan, New York, Oregon, Washington, and Wisconsin within the United States, and in China, Czech Republic, Germany, Italy, Japan, Spain and the United Kingdom. These additional facilities cover approximately 652,000 square feet, of which approximately 451,000 square feet are leased and approximately 201,000 square feet are owned.
We consider our facilities suitable and adequate for the purposes for which they are used and do not anticipate difficulty in renewing existing leases or in finding alternative facilities. We believe all our properties have been properly maintained.
Item 2 of the 10-K filed Feb 23, 2026.4
Leadership
Who has led NOVANTA INC, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerMatthijs Glastra Feb 28, 2017 to now13
- Chief executive officerCharles D. Winston Jan 10, 2006 to Mar 17, 200614
- Chief executive officerSergio Edelstein Jul 12, 2006 to Mar 31, 201015
- PresidentMatthijs Glastra Nov 1, 2012 to Mar 11, 201416
- PresidentPhilippe Brak Jul 27, 2010 to Jul 27, 201017
- PresidentCharles D. Winston Jan 10, 2006 to Mar 17, 200614
- PresidentSergio Edelstein Jul 12, 2006 to Mar 31, 201015
- Chief financial officerRobert Buckley Apr 8, 2011 to now18
- Chief operating officerCharles Guy Ravetto Jr. Jan 16, 2025 to now19
- Chief operating officerJohn Lesica Jan 16, 2025 to now20
- Chief operating officerMatthijs Glastra Mar 2, 2015 to Aug 3, 201621
Board members and other officers (45)
- Executive VP, Human ResourcesBrian S. Young Dec 14, 2016 to Mar 5, 202422
- Vice PresidentJamie B. Bader Aug 11, 2011 to Jul 26, 201323
- VP,Corp Contr,Chief Acctg OffPeter L. Chang Aug 17, 2011 to Feb 28, 202424
- Vice President, Human ResourceDeborah Mulryan Sep 8, 2011 to Sep 9, 201425
- Assoc Chief Restructuring OffGabriel P. Bresler Jul 23, 2010 to Jul 23, 201026
- Chief Restructuring OfficerMichael E. Katzenstein Jul 23, 2010 to Jul 27, 201027
- Vice PresidentPhilippe Brak Jan 7, 2008 to Mar 21, 200828
- Vice PresidentAnthony J. Bellantuoni Sep 11, 2007 to Apr 1, 201129
- Vice PresidentKurt A. Pelsue Jan 31, 2006 to Sep 19, 200730
- Vice PresidentLinda Palmer Jan 31, 2006 to Jul 26, 200631
- Vice PresidentThomas R. Swain Jan 31, 2006 to May 18, 200732
- Vice President & Gen CounselDaniel J. Lyne Jul 17, 2006 to Mar 21, 200833
- Vice PresidentFelix I. Stukalin Jul 17, 2006 to Jul 16, 200834
- Vice President & General Mgr.Ray Sansouci Jul 17, 2006 to May 28, 200835
- Managing DirectorStephen Kew Jul 17, 2006 to Feb 27, 200836
- Managing DirectorStephen Webb Jul 17, 2006 to Jul 27, 201037
- Vice President & General Mgr.Nino Federico Jul 18, 2006 to Mar 21, 200838
- Board memberMatthew Farrell Nov 5, 2025 to now39
- Board memberMary Kay Ladone Jul 12, 2024 to now40
- Board memberBarbara B. Hulit Jul 28, 2022 to Jan 6, 202541
- Board memberKatherine Ann Owen Feb 25, 2021 to Jul 8, 202442
- Board memberFrank Anders Wilson May 14, 2021 to now43
- Board memberMaxine Lum Mauricio May 27, 2020 to now44
- Board memberDeborah Disanzo May 13, 2019 to Jan 5, 202245
- Board memberLonny J. Carpenter May 14, 2018 to now46
- Board memberMatthijs Glastra Feb 28, 2017 to now13
- Board memberBrian Douglas King May 12, 2017 to Jan 5, 202247
- Board memberDominic A. Romeo Jun 26, 2012 to Jan 6, 202048
- Board memberHarry L. Bosco Jun 26, 2012 to Jan 3, 201749
- Board memberThomas N. Secor Jun 26, 2012 to now50
- Board memberDennis J. Fortino Jul 27, 2010 to Jan 3, 201851
- Board memberEugene I. Davis Jul 27, 2010 to Jan 4, 201252
- Board memberIra J. Lamel Jul 27, 2010 to Jan 5, 202253
- Board memberK. Peter Heiland Jul 27, 2010 to Feb 1, 201254
- Board memberMichael E. Katzenstein Jul 27, 2010 to Jul 27, 201055
- Board memberStephen W. Bershad Jul 27, 2010 to Jan 15, 202156
- Board memberSergio Edelstein Mar 19, 2008 to Mar 31, 201057
- Board memberCharles D. Winston Jan 10, 2006 to Mar 17, 200614
- Board memberBenjamin J. Virgilio Sep 26, 2006 to Jul 27, 201058
- Board memberByron O. Pond Sep 26, 2006 to Jan 4, 201259
- Board memberGarrett A. Garrettson Sep 26, 2006 to Jul 27, 201060
- Board memberMarina Hatsopoulos Sep 26, 2006 to Jul 27, 201061
- General counselAlexander Manganiello Dec 5, 2025 to now62
- General counselMichele Davis Welsh Jul 13, 2022 to Feb 24, 202563
- General counselDaniel J. Lyne Jul 26, 2006 to Jul 26, 200664
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ATI Automatizacion Industrial S de RL de CV. Mexico3
- ATI Industrial Automation (Lang Fang) Co., Ltd. China3
- ATI Industrial Automation, Inc. North Carolina3
- ATI Industrial Mexico, LLC North Carolina3
- Bearing Engineers, Inc. d/b/a Motion Solutions California3
- GSI Lumonics Asia Pacific Ltd. Hong Kong3
- Keonn Technologies, S.L. Spain3
- Laser Quantum Limited United Kingdom3
- Motion Solutions Parent Corp Delaware3
- NDS Surgical Imaging, LLC Delaware3
- Novanta Corporation Michigan3
- Novanta Distribution (USD) GmbH Germany3
- Novanta Europe GmbH Germany3
- Novanta Holdings BV Netherlands3
- Novanta Insurance Company Arizona3
- Novanta Italy SRL Italy3
- Novanta Japan Corporation Japan3
- Novanta Medical GmbH Germany3
- Novanta Medical Technologies Corp. Delaware3
- Novanta Medical USA, Inc.. Florida3
- Novanta Medical s.r.o. Czech Republic3
- Novanta Precision Medicine Corporation Delaware3
- Novanta Singapore Pte. Ltd. Singapore3
- Novanta Technologies (Suzhou) Co., Ltd. China3
All 31 listed subsidiaries
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Oct 2, 20268-K Financial statements and exhibits65
- Aug 5, 20268-K Results of operations66
- Jul 27, 20268-K Completed an acquisition or sale; New debt or obligation; Regulation FD disclosure67
- Jun 9, 20268-K Entered a material agreement; Regulation FD disclosure68
- Jun 9, 20268-K Entered a material agreement; Unregistered sale of shares; Other events69
- May 29, 20268-K Shareholder vote70
- May 15, 20268-K Entered a material agreement; New debt or obligation71
- May 11, 20268-K Results of operations72
- Feb 23, 20268-K Results of operations73
- Dec 1, 20258-K Regulation FD disclosure74
- Nov 13, 20258-K Regulation FD disclosure75
- Nov 12, 20258-K Entered a material agreement; New debt or obligation76
- Feb 28, 2017New chief executive Matthijs Glastra becomes CEO13
- Jul 12, 2006New chief executive Sergio Edelstein becomes CEO15
- Jan 10, 2006New chief executive Charles D. Winston becomes CEO14
Calendar
Coming up
- Nov 9, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.87 a share, on Nov 3, 2025.77
When it reported results
- Aug 5, 2026Reported quarterly or annual results66
- May 11, 2026Reported quarterly or annual results72
- Feb 23, 2026Reported quarterly or annual results73
- Nov 3, 2025Reported quarterly or annual results78
- Aug 5, 2025Reported quarterly or annual results79
- May 6, 2025Reported quarterly or annual results80
- Feb 25, 2025Reported quarterly or annual results81
- Feb 25, 2025Reported quarterly or annual results82
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
362 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 216 insider forms, 21 large holders, 53 other. The latest 20:
- Oct 2, 20268-K/A EDGAR
- Sep 15, 20264 PRIMARY DOCUMENT EDGAR
- Sep 11, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Jul 30, 2026SCHEDULE 13G/A EDGAR
- Jul 27, 20268-K EDGAR
- Jul 7, 20264 PRIMARY DOCUMENT EDGAR
- Jul 2, 2026144 EDGAR
- Jun 29, 2026S-3ASR EDGAR
- Jun 9, 20268-K EDGAR
- Jun 9, 20268-K EDGAR
- Jun 4, 20264 PRIMARY DOCUMENT EDGAR
- Jun 2, 2026144/A EDGAR
- Jun 2, 2026144 EDGAR
- May 29, 20268-K EDGAR
- May 29, 2026SD EDGAR
- May 15, 20268-K EDGAR
- May 14, 20264 PRIMARY DOCUMENT EDGAR
The 362 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
65 open-market trades by officers, directors and large owners since October 2021: 0 buys and 65 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Secor Thomas NDirector | Sale | 663 | $147.60 | $97.9K | Form 4 |
| Jul 2, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $161.13 | $1.0M | Form 4 |
| Jun 2, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $168.66 | $1.1M | Form 4 |
| May 12, 2026 | Glastra MatthijsChief Executive Officer | Sale | 7,500 | $150.43 | $1.1M | Form 4 |
| May 5, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $131.13 | $852.3K | Form 4 |
| Apr 17, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $130.05 | $845.3K | Form 4 |
| Mar 16, 2026 | Buckley RobertChief Financial Officer | Sale | 9,957 | $116.77 | $1.2M | Form 4 |
| Mar 2, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $138.34 | $899.2K | Form 4 |
| Feb 20, 2026 | Buckley RobertChief Financial Officer | Sale | 1,423 | $140.88 | $200.5K | Form 4 |
| Feb 10, 2026 | Glastra MatthijsChief Executive Officer | Sale | 7,500 | $145.04 | $1.1M | Form 4 |
| Feb 2, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,500 | $135.15 | $878.5K | Form 4 |
| Jan 21, 2026 | Buckley RobertChief Financial Officer | Sale | 1,423 | $140.14 | $199.4K | Form 4 |
| Jan 21, 2026 | Glastra MatthijsChief Executive Officer | Sale | 7,500 | $140.00 | $1.1M | Form 4 |
| Jan 9, 2026 | Glastra MatthijsChief Executive Officer | Sale | 6,177 | $130.00 | $803.0K | Form 4 |
| Jan 8, 2026 | Glastra MatthijsChief Executive Officer | Sale | 323 | $130.14 | $42.0K | Form 4 |
| Dec 22, 2025 | Secor Thomas NDirector | Sale | 747 | $120.16 | $89.8K | Form 4 |
| Dec 15, 2025 | Secor Thomas NDirector | Sale | 748 | $119.67 | $89.5K | Form 4 |
| Dec 4, 2024 | Buckley RobertChief Financial Officer | Sale | 1,617 | $170.16 | $275.1K | Form 4 |
| Dec 2, 2024 | Glastra MatthijsChief Executive Officer | Sale | 2,000 | $168.51 | $337.0K | Form 4 |
| Dec 2, 2024 | Buckley RobertChief Financial Officer | Sale | 2,041 | $168.23 | $343.4K | Form 4 |
All 65 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G, 6 filings Feb 14, 2022 to Aug 14, 202683
- BlackRockSCHEDULE 13G/A, 5 filings Feb 3, 2022 to Jul 30, 202684
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202685
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202686
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 202687
- Neuberger BermanSC 13G/A, 2 filings Feb 14, 2022 to Feb 10, 202388
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Matthijs Glastra | 57 | $863.0K | $10.0M89 |
| 2025 | Robert J. Buckley | $569.8K | $4.8M89 | |
| 2025 | John Lesica | $499.4K | $3.9M89 | |
| 2025 | Charles G. Ravetto | $491.9K | $2.3M89 | |
| 2025 | Michele D. Welsh | $230.9K | $2.2M89 | |
| 2025 | Alexander Manganiello | $19.8K | $19.9K89 | |
| 2024 | Chief Executive Officer | $826.3K | $8.8M89 | |
| 2024 | Chief Financial Officer | $546.1K | $3.9M89 | |
| 2024 | Former General Counsel and Corporate Secretary | $376.9K | $1.4M89 | |
| 2023 | Chief Executive Officer | $784.4K | $8.3M89 | |
| 2023 | Chief Financial Officer | $521.9K | $3.4M89 | |
| 2023 | Former General Counsel and Corporate Secretary | $362.8K | $1.3M89 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| May 18, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −15.4% | Report |
| Nov 13, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +9.1% | Report |
| Aug 4, 2025 | Lisa C. McClainRepublican, House | Sale | $1,001 - $15,000 | +13.6% | Report |
| Jul 22, 2025 | Lisa C. McClainRepublican, House | Buy | $1,001 - $15,000 | −14.1% | Report |
| Jul 25, 2022 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +104.1% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How NOVANTA INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARNOVANTA INC1
- CIK0001076930
- Employer ID (EIN)98-01104124
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
- Incorporated inNew Brunswick, Canada4
- Fiscal year endsDecember 311
- Industry code (SIC)3690 Miscellaneous Electrical Machinery, Equipment & Supplies1
- SEC reviewing officeOffice of Manufacturing, Division of Corporation Finance1
- Business address125 Middlesex Turnpike, ., Bedford, MA 017301
- Phone781-266-56181
- Shares outstanding37,817,770 as of Jul 29, 202611
- Public float$3.5T as of Jun 27, 20254
- AuditorDeloitte & Touche LLP, Boston, Massachusetts, United States PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJan 29, 19991
- Filings1,551 in all: 4 (688), 8-K (301), 10-Q (83), SC 13D/A (63), SC 13G/A (62), 3 (55), SC 13G (31), 144 (30)1
All 56 form types
4/A (28), DEF 14A (27), 10-K (25), SD (13), 8-K/A (11), ARS (10), SC 13D (9), NT 10-Q (8), PRE 14A (8), S-8 (8), 5 (7), SC TO-T/A (6), 425 (5), UPLOAD (5), CORRESP (4), DEFA14A (4), S-3 (4), S-3ASR (4), SCHEDULE 13G/A (4), 10-K/A (3), 10-K405 (3), EFFECT (3), NT 10-K (3), SC TO-C (3), SCHEDULE 13G (3), 10-Q/A (2), 3/A (2), 424B5 (2), 8-A12B (2), 8-A12G (2), S-3/A (2), S-4/A (2), 144/A (1), 25-NSE (1), 424B1 (1), 424B3 (1), 424B7 (1), CERT (1), CERTNAS (1), CT ORDER (1), DEFR14A (1), FWP (1), POSASR (1), PREC14A (1), S-4 (1), SC TO-T (1), T-3 (1), T-3/A (1)
- Latest filingsAnnual report (10-K) Feb 23, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 24, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common shares, no par value | NOVT | The Nasdaq Global Select Market |
| 6.50% Tangible Equity Units | NOVTU | The Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 23, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks NOVANTA INC names in Item 1A of its 10-K filed Feb 23, 2026: 38 risks under these headings, as written.4
- Risks Relating to Our Business
- Our results of operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and levels of business activities.
- Our business success depends upon our ability to respond to fluctuations in product demand, but doing so may require us to incur costs despite limited visibility into future business declines.
- The success of our business depends on our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively.
- Customer order timing and other factors may cause our operating results to fluctuate from period to period.
- Our business may be adversely affected by cyberattacks or other incidents that cause significant disruption in, or breach the security of, our information technology systems or those of our third-party providers.
- Our reliance on international operations subjects us to risks not typically faced by companies operating exclusively in the U.S.
- Increased component outsourcing to manufacturers located in different countries than our manufacturing facilities leads to additional risks that could negatively impact our business.
- Increases in tariffs, trade restrictions or taxes on our products could have an adverse impact on our results of operations.
- Our operating results depend in part on our ability to contain or reduce costs. There is substantial price competition in our industry and upward pressure on material and labor costs. Our success and profitability will depend on our ability to maintain a competitive cost and price structure.
- Others may violate our intellectual property rights and cause us to incur significant costs to protect our rights.
- Our operating results would suffer if we are unable to successfully defend against infringement claims by third parties.
The other 27 risks
- We operate in highly competitive industries and, if we lose competitive advantages, our business would suffer adverse consequences.
- Our results of operations will be adversely affected if we fail to identify suitable acquisition candidates, complete acquisitions, successfully integrate recent and future acquisitions or grow the acquired businesses as planned.
- If we do not attract and retain our key personnel, our ability to execute our business strategy will be limited.
- We have undertaken restructuring and realignment activities in the past, and we will continue to assess our operating and cost structure in the future. These actions may not improve our financial position, and may ultimately prove detrimental to our operations and sales.
- Product defects or problems with integrating our products with other vendors’ products used by our customers may seriously harm our business and reputation.
- Disruptions in the supply of certain key components and other goods from our suppliers, including limited or single source suppliers, have adversely affected the results of our business operations, and could damage our relationships with customers.
- If we fail to accurately forecast component and raw material requirements for our products, we could incur additional costs and experience significant delays in shipments, which could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
- Production difficulties and product delivery delays or disruptions could have a material adverse effect on our business.
- We are subject to extensive and dynamic medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products.
- Our products and operations are subject to various foreign and U.S. federal and state healthcare laws and regulations, which could expose us to penalties.
- Our business is indirectly subject to healthcare industry cost containment and healthcare reform measures that could result in reduced sales of our products.
- Changes in government regulations related to our business or our products could reduce demand for our products or increase our expenses.
- Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements may adversely impact our business and financial results.
- If we fail to implement new information technology systems successfully, our business could be adversely affected.
- Changes in foreign currency rates could have a material adverse effect on our financial position, results of operations, and cash flows.
- Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets.
- Our reliance upon OEM customers subjects us to credit, inventory, and business failure risks beyond our control.
- The loss of sales, or significant reductions in orders from, any major customers may have a material adverse effect on us.
- Increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability and responsibility practices may cause us to incur additional costs or expose us to additional risks.
- The effects of climate change and related regulatory responses may adversely impact our business.
- Risks Relating to Taxes
- Novanta Inc. may be subject to U.S. federal income taxation even though it is a non-U.S. corporation.
- Our effective tax rate is subject to fluctuation, which could impact our financial position and earnings per share.
- Risks Relating to Our Common Shares and Our Capital Structure
- We may require additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, but this capital may not be available on acceptable terms or at all.
- Our existing indebtedness could adversely affect our future business, financial condition and results of operations.
- General Risk Factors
- The market price for our common shares may be volatile.
- We are exposed to the credit risk of some of our customers and to credit exposures in weakened markets, which could adversely affect our results of operations.
- If we fail to maintain appropriate internal controls in the future, we may not be able to report our financial results accurately, which may adversely affect our stock price and our business.
Legal proceedings
The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. See Note 18 to Consolidated Financial Statements for additional information about legal proceedings involving the Company.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARNOVANTA INC filings on SEC EDGAR
- 2SEC EDGARNOVANTA INC filings on SEC EDGAR
- 3
- 4
- 5SEC EDGARNOVANTA INC 10-K for fiscal 2025
- 6SEC EDGARNOVANTA INC 10-K for fiscal 2019
- 7SEC EDGARNOVANTA INC 10-K for fiscal 2020
- 8SEC EDGARNOVANTA INC 10-K for fiscal 2021
- 9SEC EDGARNOVANTA INC 10-K for fiscal 2022
- 10SEC EDGARNOVANTA INC 10-Q for fiscal 2026
- 11SEC EDGARNOVANTA INC 10-Q for fiscal 2026
- 12SEC EDGARNOVANTA INC 10-K for fiscal 2019
- 13
- 14
- 15
- 16SEC EDGARMatthijs Glastra, President
- 17SEC EDGARPhilippe Brak, President
- 18
- 19
- 20SEC EDGARJohn Lesica, Chief operating officer
- 21
- 22
- 23SEC EDGARJamie B. Bader, Vice President
- 24
- 25
- 26
- 27
- 28SEC EDGARPhilippe Brak, Vice President
- 29
- 30SEC EDGARKurt A. Pelsue, Vice President
- 31SEC EDGARLinda Palmer, Vice President
- 32SEC EDGARThomas R. Swain, Vice President
- 33
- 34SEC EDGARFelix I. Stukalin, Vice President
- 35
- 36SEC EDGARStephen Kew, Managing Director
- 37SEC EDGARStephen Webb, Managing Director
- 38
- 39SEC EDGARMatthew Farrell, Board member
- 40SEC EDGARMary Kay Ladone, Board member
- 41SEC EDGARBarbara B. Hulit, Board member
- 42SEC EDGARKatherine Ann Owen, Board member
- 43SEC EDGARFrank Anders Wilson, Board member
- 44SEC EDGARMaxine Lum Mauricio, Board member
- 45SEC EDGARDeborah Disanzo, Board member
- 46SEC EDGARLonny J. Carpenter, Board member
- 47SEC EDGARBrian Douglas King, Board member
- 48SEC EDGARDominic A. Romeo, Board member
- 49SEC EDGARHarry L. Bosco, Board member
- 50SEC EDGARThomas N. Secor, Board member
- 51SEC EDGARDennis J. Fortino, Board member
- 52SEC EDGAREugene I. Davis, Board member
- 53SEC EDGARIra J. Lamel, Board member
- 54SEC EDGARK. Peter Heiland, Board member
- 55SEC EDGARMichael E. Katzenstein, Board member
- 56SEC EDGARStephen W. Bershad, Board member
- 57SEC EDGARSergio Edelstein, Board member
- 58SEC EDGARBenjamin J. Virgilio, Board member
- 59SEC EDGARByron O. Pond, Board member
- 60SEC EDGARGarrett A. Garrettson, Board member
- 61SEC EDGARMarina Hatsopoulos, Board member
- 62
- 63SEC EDGARMichele Davis Welsh, General counsel
- 64SEC EDGARDaniel J. Lyne, General counsel
- 65SEC EDGARFinancial statements and exhibits
- 66SEC EDGARResults of operations
- 67
- 68
- 69
- 70SEC EDGARShareholder vote
- 71
- 72SEC EDGARResults of operations
- 73SEC EDGARResults of operations
- 74SEC EDGARRegulation FD disclosure
- 75SEC EDGARRegulation FD disclosure
- 76
- 77NasdaqNasdaq calendar
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89